Clinical trials: Meningioma Atypical
Brain and Central Nervous System Tumors, Lymphoma
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00053118
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Brain and Central Nervous System Tumors, Chordoma
Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer
RATIONALE: Polyvinylpyrrolidone-sodium hyaluronate gel may lessen the pain of oral mucositis, or mouth sores, in patients undergoing treatment for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chordoma, Kidney Cancer, Leukemia
- Trial name
- NCT00349024
- Testing
- polyvinylpyrrolidone-sodium hyaluronate gel
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138216
- Testing
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Where
- 18 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Meningioma Atypical
Multisession Radiosurgery in Residual/Recurrent Grade II Meningiomas.
Fractionated radiosurgery will be delivered to atypical meningioma lesions in salvage setting for patients who present post-surgical residual lesion or develop recurrence.
- Trial name
- ATM (NCT05081908)
- Testing
- Radiosurgery
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Meningiomas
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.
- Trial name
- NCT02648997
- Testing
- Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, Nivolumab - 480 mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00100880
- Testing
- lenalidomide, perfusion-weighted magnetic resonance imaging, diffusion-weighted magnetic resonance imaging
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Brain and Central Nervous System Tumors, Leukemia
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
RATIONALE: Gathering information about why patients or their guardians agree or decline to participate in the optional pharmacokinetic portion of a phase I treatment study may help doctors plan clinical trials in the future.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00890435
- Testing
- questionnaire administration, psychosocial assessment and care
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Meningioma
Carbon Ion Radiotherapy for Atypical Meningiomas
Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. With this approach, local control ranges between 50 and 70%, depending on resection status.
- Trial name
- MARCIE (NCT01166321)
- Testing
- Carbon Ion Radiotherapy
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- University Hospital Heidelberg
Recurrent Atypical/malignant Meningioma
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed…
- Trial name
- NCT04501705
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Beijing Sanbo Brain Hospital
Atypical Meningioma, Clear-cell Meningioma
Oncological Care for Patients With Meningioma
Meningiomas with malignant components include grade II meningiomas (GIIM, the most common ones) and grade III meningiomas (GIIIM). They represent 5-35% of all meningiomas.
- Conditions
- Atypical Meningioma, Clear-cell Meningioma, Chordoid Meningioma, Anaplastic Meningioma
- Trial name
- ATYPICMENING (NCT02973256)
- Where
- France
- Volunteers
- 1,204 people
- Sponsor
- University Hospital, Montpellier
Meningioma
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
- Trial name
- STELLAR-201 (NCT07428616)
- Testing
- Zanzalintinib
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Exelixis
Meningioma Atypical, Radiotherapy
Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection
Postoperative adjuvant radiotherapy is a key component of comprehensive treatment of meningioma. However, for atypical meningioma after total resection, there is still a huge controversy in patients who need adjuvant radiotherapy…
- Conditions
- Meningioma Atypical, Radiotherapy, Progression-Free Survival, Adverse Effect of Radiation Therapy
- Trial name
- NCT04127760
- Testing
- radiotherapy
- Volunteers
- 140 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Anaplastic (Malignant) Meningioma, Atypical Meningioma
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas.
- Conditions
- Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma
- Trial name
- NCT02847559
- Testing
- Bevacizumab, Electric Field Therapy, NovoTTF-200A Device
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Anaplastic Astrocytoma, Anaplastic Ependymoma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma
- Trial name
- NCT03434262
- Testing
- Gemcitabine, ribociclib, sonidegib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Atypical Meningioma
Study of the Inflammatory Microenvironment in Atypical Meningiomas
Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy.
- Trial name
- NCT04761653
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Central Hospital, Nancy, France
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Brain Cancer
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a…
- Trial name
- NCT01892397
- Testing
- Optune (NovoTTF-100A)
- Where
- 9 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with…
- Trial name
- NCT00015899
- Testing
- lonafarnib
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pediatric Brain Tumor Consortium